Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) EBT Margin (2022 - 2025)

Historic EBT Margin for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to 529.43%.

  • 60 Degrees Pharmaceuticals' EBT Margin rose 10672900.0% to 529.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 845.26%, marking a year-over-year increase of 7722800.0%. This contributed to the annual value of 1309.37% for FY2024, which is 1945500.0% up from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' EBT Margin is 529.43%, which was up 10672900.0% from 1717.42% recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' EBT Margin peaked at 8153.48% during Q3 2023, and registered a low of 15126.2% during Q1 2023.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median EBT Margin value was 1372.26% (recorded in 2024), while the average stood at 1722.9%.
  • Data for 60 Degrees Pharmaceuticals' EBT Margin shows a peak YoY increase of 155312600bps (in 2024) and a maximum YoY decrease of -97502000bps (in 2024) over the last 5 years.
  • 60 Degrees Pharmaceuticals' EBT Margin (Quarter) stood at 4492.13% in 2022, then tumbled by -136bps to 1628.06% in 2023, then soared by 48bps to 848.15% in 2024, then skyrocketed by 38bps to 529.43% in 2025.
  • Its last three reported values are 529.43% in Q3 2025, 1717.42% for Q2 2025, and 1147.79% during Q1 2025.